In This Section:
Diabetes
CV Outcomes in Diabetes
Risk reduction with antihyperglycaemic therapies
Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D).
The opportunity for CV disease prevention in patients with T2D has recently expanded with antihyperglycaemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE). Although the exact mechanisms of CV benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects. These agents have triggered a shift beyond glucose control, to a broader strategy of comprehensive CV risk reduction.
CV specialists are well-positioned to play a key role in managing patients with T2D, including screening, aggressively treating CV risk factors, and incorporating the use of antihyperglycaemic agents into routine practice.
Section Advisor
Professor Mikhail N Kosiborod
Saint Luke's America Heart Institute, Kansas City, MO, US
The Radcliffe diabetes and CVD risk program is supported by an educational grant from Novo Nordisk.
Video
Video Series
Video Series
Video
Video Series
Broadcast
e-SPACE CRM 2023 – Day Two
Broadcast
e-SPACE CRM 2023 – Day One
Broadcast
Video
Video
Video Series
External Article
Once-weekly semaglutide in adults with overweight or obesity
External Article
SGLT2 inhibitors: expanding their Empire beyond diabetes
External Article
Prevention of heart failure events with SGLT-2 inhibitors across a…
Recent Videos
Video
Video Series
Video
Video
Video Series